Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan.
The investment will help get the company’s next-generation antibiotic through phase III clinical trials.
Edwards will be adding the role of chairman to his responsibilities as chief executive.
